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In this work, synthesis of alkylamino and aralkylamino derivatives of sesquiterpene quinone 
avarone and its model compound tert-butylquinone was described. For all obtained derivatives 
biological activity was studied. Cytotoxic activity of the synthesized derivatives towards 
multidrug resistant MDR human non-small cell lung carcinoma NCI-H460/R cells, their sensitive 
counterpart NCI-H460 and human normal keratinocytes (HaCaT) as well as detection of cell 
death superoxide anion generation were investigated. Antimicrobial activity towards Gram 
positive and Gram negative bacteria and fungal cultures was determined. The results showed that 
strong cytotoxic activity toward cancer cells was improved with simple avarone mimetics. Some 
derivatives were selective towards MDR cancer cells. The most active derivatives induced 
apoptosis in both cancer cell lines, but not in normal cells. Superoxide production was induced by 
2,6-disubstituted compounds in MDR cancer cells and not by less active 2,5-disubstituted 
compounds and was accompanied by the collapse of the mitochondrial transmembrane potential. 
Two tert-butylquinone derivatives were particularly selective towards MDR cancer cells. Some 
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A major factor preventing successful cancer treatment is development of resistance to 
chemotherapeutics. The mechanisms of drug resistance include: overexpression of 
transmembrane drug efflux pumps, alterations in drug targets, activation of prosurvival pathways 
and ineffective induction of cell death [1]. Besides intrinsic resistance developed during 
carcinogenesis, initially sensitive cancer cells can develop acquired resistance after 
administration of single chemotherapeutic. The occurrence of multidrug resistance (MDR) 
phenotype is a serious obstacle to efficient cancer treatment. Therefore, targeting MDR cells is 
one of principal goals in the development of new anticancer drugs. 
Marine sponges are well known as prolific sources of bioactive metabolites with diversity of 
structures. Sesquiterpene quinones, in particular, are known as compounds with a wide range of 
biological activities, including antibacterial activity [2], promotion of TNF-α production [3], 
antidiabetic activity due to inhibition of tyrosine phosphatase 1B (PTP1B) [4,5], inhibition of 
farnesyl diphosphate synthase [6], antiproliferative activity under normoxic and hypoxic 
conditions [7,8], and protein kinase inhibitory activity [9]. Activity in various cancer cell lines 
has been also in focus for the investigation of this class of compounds. Numerous isolated and 
synthesized sesquiterpenoid quinones displayed anticancer activity against, among others,  HeLa 
and HepG2 cell lines [10,11], multiple myeloma [12], and NCI-H460 cell line [13].  
Avarol/avarone, a redox pair with versatile biological activity was isolated from marine sponge 
Dysidea avara. Both compounds displayed strong cytotoxic activity toward K-562 and Fem-X 
cell lines [14], T-lymphocyte DNA inhibition activity [15], and anti-HIV activity [16].  
Our previous results have shown that some alkylamino derivatives of avarone, in particular 4’-
(methylamino) derivative were selective toward cancer cell lines in comparison with normal cell 
lines [14]. In addition, a significant difference in the activity between two regioisomers was 
found, likely precluding non-specific mode of action.  
When dealing with natural products derivatives, the source availability has to be considered. 
Avarol, the precursor compound, is the major constituent of the sponge Dysidea avara (3 g/kg 
sponge) [17]. In order to secure sustainable production of avarol, various attempts were made on 
cultivation of sponge and/or cell culture [18,19]. Still, the problem of supplying sufficient amount 
of avarol remains.  
One solution to this problem is to consider avarol/avarone as model for design of active 
substances. In this study, a relatively crude model was used, based on a simple quinone, tert-
butylquinone (TBQ). tert-Butyl group was selected for several reasons. First, it is a hydrophobic 
group, but with fewer carbon atoms, so that modifications in the substituents can be performed, 
affording derivatives with different hydrophobicites. Second, this group is voluminous, which is 
important since there is a considerable steric bulk in avarone sesquiterpene moiety. Third, the 
group is achiral, avoiding problems with molecular asymmetry. Fourth, since the mechanisms of 
action of avarone derivatives might include radical intermediates, the bulky tert-butyl group 
might help in stabilization of semiquinone radicals. Finally, the starting compound, tert-
butylquinone, is readily available. 
Both TBQ and its hydroquinone (TBHQ) induce cytotoxicity, with TBQ having a greater effect. 
Both compounds induce decreased mitochondrial membrane potential, disruption of 
mitochondrial structure with formation of cytosolic vacuoles, release of cytochrome c from 
mitochondria, caspase activation, PARP cleavage and the decrease of intracellular GSH and ATP 
[20,21].  
Biological activity of quinones is dual. It is a combination of Michael addition to enone system 
and generation of oxygen reactive species (ROS) in redox cycle between quinone and its 
hydroquinone counterpart via semiquinone anion radical. Studies have shown that TBQ at a low 
dose induces DNA damage by forming 8-hydroxydeoxyguanosine due to generation of reactive 
oxygen species (ROS) [22]. TBHQ is O2
.-
 scavenger with IC50 of 18.1 μM [23,24]. 
In this work, a series of of alkylamino and aralkylamino derivatives of avarone and TBQ were 
synthesized, and their cytotoxic activity was tested against three cell lines, non-small cell lung 
cancer, both sensitive and MDR, NCI-H460 and NCI-H460/R, respectively, and normal human 
keratinocytes HaCaT. The type of cell death was discriminated by AV/PI staining, while DHE 
fluorescent probe was employed to assess superoxide anion generation ability. Mitochondrial 
transmembrane potential (ΔΨm) was also assessed. Cyclic voltammetry was used to measure 
half-wave potentials of synthesized compounds in two-stage redox system quinone–semiquinone 
radical–hydroquinone. In addition, antibacterial and antifungal activities were determined. 
Results and Discussion. 
Hydroquinones (tert-butylhydroquinone and avarol) were oxidized by silver(I) oxide to 
corresponding quinones 1 and 2. Quinones were treated with amines to yield two regioisomers of 
aminoquinones 3a-i and 4a-i. The reaction steps are addition of an amine to form the substituted 
hydroquinone intermediate, which is immediately oxidized by the excess of the starting quinone. 
With tert-butylquinone 2,6-disubstituted quinone product by far dominated 2,5-disubstituted 
product in the mixture, while with avarone  the excess of 2,6- product was much less pronounced, 
so that with phenethyl amine the major product was 2,5- product. The exception in the synthetic 
route is preparation of ethylamino derivatives 3b and 4b, which were obtained in the reaction of 
the quinone with diethylamine, in which the initial addition product undergoes Hoffman-like 
elimination [25] which results in low yields of products. 
All 3 derivatives display long-range W coupling between quinone protons with 
4
J around 2 Hz, 
resulting with signals of these hydrogens to be dublets. On the other hand, 4 derivatives’ quinone 
protons are five bonds away and their long-range coupling is too small to be detected, resulting in 
their signals to be singlets. Additionally, experimentally measured 
13
C shifts of quinone core 
carbons showed good correlation with expected values calculated from basic benzoquinone 
known shifts and adding alkyl and alkylamino/aralkylamino substituents contributions, showing 
different patterns for 3 and 4 series of compounds. This way it was possible to make 
unambiguous distinction between 3 and 4 regioisomers (Scheme 1). 
 
 
For all the synthesized compounds, half-wave potentials were recorded at glassy carbon disk 
(3mm diameter) in dimethyl sulfoxide against silver wire immersed in electrolyte solution 
containing 0.01 M silver ions as the reference electrode, and ferrocene as reference compound. 
Results are given in Table 1 and Fig. 1. 
Cyclic voltammograms of avarone amino derivatives show typical behavior of 
quinone/hydroquinone redox pair. Two waves, corresponding to reversible or quasireversible one 
electron processes were observed. The reversibility of the first wave attributed to 
quinone/semiquinone anion radical redox system, was not perturbed by derivatization. Similarly, 
second wave assigned to semiquinone anion radical/hydroquinone dianion redox system behaves 
as quasireversible.  
As expected, amino derivatization of avarone moiety led to negative shift of first reduction peak 
potentials with respect to avarone. tert-Butylquinone derivatives were reduced at slightly more 
negative potential, due to a greater electron donating ability of tert-butyl group. Aralkyl 
derivatives were reduced at a slightly less negative potential probably due to a slight electron 
withdrawing effect of phenyl group. Changes in length of the side chain did not produce 
significant effect on the redox properties, as expected. Finally, 2,5-disubstituted derivatives were 
always, except for the small methylamino substituent, reduced at a more negative potential. 
Consequently, similar behavior of avarone and its tert-butyl analogue justifies application of the 
latter as model system of avarone.  
 
Anticancer activity. The anticancer effects of several TBQ derivatives were compared with their 
avarone counterparts (3c-4c vs. 3g-4g, 3d-4d vs. 3h-4h, and 3f-4f vs. 3i-4i). Cytotoxic activity 
was investigated in MDR human non-small cell lung carcinoma NCI-H460/R cells, their sensitive 
counterpart NCI-H460 and human normal keratinocytes (HaCaT). The differences in response 
between cancer and normal cells were assessed by MTT after 72 h treatment (Table 2). Most of 
2,5-disubstituted quinone derivatives, except 4a and 4b showed selectivity towards cancer cell 
lines (Table 2, Fig. S1). Derivative 4h was the least active in all tested cell lines. Although less 
selective, 2,6-disubstituted derivatives exhibited higher cytotoxicity than the corresponding 2,5-
disubstituted derivatives (Table 2, Fig. S1). Importantly, the presence of MDR phenotype in NCI-
H460/R cells did not diminish the efficacy of tested compounds, with the exception of 4c. Even 
more, some derivatives exerted prominent activity against MDR cells (3e and 4e, 3f, 3g and 4g, 
3i and 4i). The IC50 values for two compounds, 2-tert-butyl-6-(phenethylamino)-1,4-
benzoquinone (3f) and 3’-(butylamino)avarone (3g) were less than 10 μM in cells with the MDR 
phenotype. 
When comparing activities of tert-butylquinone derivatives with avarone counterparts, it can be 
noticed that the former ones are generally more selective to cancer cell lines. Among TBQ 
derivatives aralkyl ones showed the best activity and selectivity to both sensitive and MDR 
cancer cells. Within the avarone series, large alkylamino derivatives were less active, probably 
due to excessively high log P. According to cytotoxicity evaluation, the most promising 
derivatives are: 2-tert-butyl-6-(phenethylamino)-1,4-benzoquinone (3f), 3’-(butylamino)avarone 
(3g) and 3’-(phenethylamino)avarone (3i) due to their high activity and good selectivity to the 
MDR cancer cell line (Table 2). For comparison, parent compounds TBQ (1) and avarone (2) 
were less potent than their derivatives, while cisplatin (CDDP), an FDA-approved drug for non-
small cells lung carcinoma treatment [26], showed strong cytotoxicity towards MDR cancer cells, 
but even stronger cytotoxicity towards normal human keratinocytes (Table 2). 
 
Then, the type of cell death induced by 25 M of tert-butyl compounds 3d-4d, 3f-4f and by their 
sesquiterpene counterparts 3h-4h, 3i-4i was compared to parent compounds 1, 2 and control 
compound CDDP (Table 3, Fig. S2). The results analyzed after 72 h showed the highest increase 
in necrotic cells (AV–PI+). tert-Butyl compounds, particularly 3f, significantly increased a 
portion of apoptotic cells (AV+PI– and AV+PI+). Therefore, it is reasonable to assume that 
increase in fraction of dead cells after 72 h is a consequence of apoptotic cell death in case of 
tert-butyl compounds. On the contrary, necrosis seems to be the type of death induced by avarone 
derivatives 3h and 3i (Figs. S2 and S4). Also, with tert-butyl compounds, 2,6-derivatives (3d, 3f 
and 3i) induced a significantly higher fraction of apoptotic cells than 2,5-derivatives (4d, 4f and 
4i). Selectivity towards cancer cells was additionally confirmed with 3d and 3f, while 3f was 
considerably more active against MDR cancer cells (Table 3, Figs. S2 and S4). CDDP and 2 
showed pro-apoptotic activity against all three cell lines showing no selectivity to cancer cells 
(Table 3, Fig. S3). 
 
In addition to genomic DNA damage, many anticancer drugs act on multiple cellular levels 
affecting different organelles and signaling pathways. One of the proposed mechanisms behind 
their toxicity is the generation of ROS, which mostly affect the mitochondrial function [27]. 
Quinones are generally thought to exhibit their toxicity through oxygen activation by redox 
cycling and alkylation of essential macromolecules [28]. However, their biological effect can be 
cell type-dependent as it was reported that p-benzoquinone cytotoxicity correlated with ROS 
formation in primary rat hepatocytes, but not in PC12 cells. Furthermore, tert-butylhydroquinone 
was shown to exhibit anticancer effect through the ability to induce phase II xenobiotic 
metabolizing enzymes via an Nrf2-dependent pathway [29].  
Therefore, in this work the potential of quinone derivatives to generate superoxide anions in 
resistant NCI-H460/R cells was examined by dihydroethidium (DHE) staining (Fig. 2).  
Mean DHE fluorescence intensity showed significant potential of 2,6-disubstituted derivatives 
(3d, 3h, 3f and 3i)  to generate superoxide anions in MDR cancer, while treatment with 2,5-
disubstituted derivatives (4d, 4h, 4f and 4i) was not prooxidative compared to untreated control 
(Fig. 2A). This effect was more pronounced with avarone derivatives (3h and 3i). The higher 
activity of 2,6-disubstituted compounds cannot be directly ascribed to differences of redox 
properties, since there is no significant difference in their electrochemical parameters (E
0
1 is more 
negative for 2,5-disubstituted compounds for only 0.01–0.02 V). Therefore, the elevation of ROS 
levels could be the consequence of the antioxidant enzymes activity modulation. As described 
previously [30], MDR cancer cells (NCI-H460/R) have lower antioxidant capacity than their 
corresponding sensitive counterpart (NCI-H460). Particularly, the expression of MnSOD enzyme 
(responsible for superoxide anion metabolism) is significantly decreased in MDR cancer cells. 
Consequently, 3d, 3f and 3h showed different pattern of action in sensitive NCI-H460 by 
lowering the superoxide anion content (Fig. 2A) which is in accordance with previous findings 
that TBHQ acts as O2
.-
 scavenger [23]. A putative target responsible for different mode of action 
in MDR cancer cells and assumed as a mechanism of selectivity towards MDR cancer cells 
remains to be identified, which will be a subject of further studies. In normal cells, TBQ 
derivatives 3d and 3f did not change superoxide anion content, while corresponding avarone 
derivatives 3h and 3i increased its production although showing weaker pro-oxidative effect than 
that observed in MDR cancer cells (Fig. 2A). Control compound 2 was pro-oxidative in MDR 
cancer cells, while CDDP induced increase in O2
.-
 production in all tested cell lines (Fig. 2A). 
The representative flow-cytometric profile of 3d and 3f-induced DHE fluorescence is shown in 
Fig. 2B.  
Besides regulation of fundamental cellular processes such as respiration and oxidative 
phosphorylation, mitochondria also provide signals that trigger apoptosis [31]. Cytochrome c 
release from mitochondria is a central event in apoptosis initiation, which induces the assembly 
of the apoptosome required for activating downstream caspases [32,33]. Mitochondrial 
membrane potential (∆Ψm) is vital for ATP generation and major loss of ∆Ψm is generally 
followed by substantial cell death. ∆Ψm and ROS levels give valuable insight into the 
physiological condition of the cell and are good indicators of mitochondrial dysfunction and 
oxidative stress. Several p-benzoquinones were reported to disrupt mitochondrial membrane 
potential in rat hepatocytes and ROS formation in PC12 cells [28]. tert-Butylhydroquinone and 2-
tert-butyl-1,4-benzoquinone were shown to display a strong anticancer potential [29]. These 
compounds decreased the mitochondrial membrane potential, disturbed the mitochondrial 
structure, caused the mitochondrial release of cytochrome c, activated caspases and induced poly 
ADP ribose polymerase (PARP) cleavage in human monocytic leukemia U937 cells [20]. Our 
study has shown that superoxide production induced by 3d was accompanied by the collapse of 
the mitochondrial transmembrane potential (ΔΨm). The results were assessed by JC-1 assay in 
cancer (NCI-H460 and NCI-H460/R ) and normal (HaCaT) cells (Fig. 3). As quantified by flow-
cytometry, 25 M 3d and 3f  induced  prominent depolarization  of mitochondrial membrane in 
cancer cells, while normal cells mitochondria remained unaffected. It is striking that the loss of 
mitochondrial potential after 3d and 3f application was detected in sensitive as well in MDR 
cancer cells despite different pattern of action (anti- vs. pro-oxidative) observed in NCI-H460 and 
NCI-H460/R cells. Thus, we assume that mitochondria of both sensitive and MDR cancer cells 
are susceptible to redox imbalance no matter whether it was caused by decrease or increase in 
superoxide anion content. CDDP and 1 did not change mitochondrial membrane potential. 
However, it must be emphasized that dead cells after CDDP treatment were removed during 
experimental procedure and not analyzed. Therefore, the majority of survived cells were resistant 
to CDDP showing no difference in comparison with control untreated cells. The change in JC-1 
fluorescence from red to green was visualized on a fluorescent microscope (Fig. 3B). 
 
Antimicrobial activity. Compounds 3a-i and 4a-i were assayed for their antimicrobial activity 
against Gram-negative and Gram-positive bacterial and fungal strains. Their activity was 
compared to commercial antibiotic, amikacin, and antimicotic, nystatin. Results are shown in 
Tables 4 and 5.  
Antibacterial activity evaluation showed that the most sensitive bacterial strains were E. coli, S. 
aureus and M. luteus (ATCC 10240). Antibacterial activity similar to that of amikacin was found 
for compounds 3c, 3e and 3f against E. coli and S. aureus, while against M. luteus (ATCC 10240) 
derivatives 3c and 3e exhibited better antibacterial activity than amikacin. Slightly weaker 
activity but still similar to that of amikacin was achieved by 4c against E. coli, by 3b and 4a 
against S. aureus and by 3b and 4e against M. luteus (ATCC 10240). Other derivatives showed a 
weak activity, while compound 3d and derivatives with sesquiterpene moiety did not show any 
antibacterial activity. Based on the results, the structural requirements for good antibacterial 
activity are tert-butylquinone scaffold, 2,6-disubstitution and aralkylamino or medium-sized 
alkylamino substituent. It should also be pointed out that MIC values for 3c, 3e and 3f are lower 
than IC50 values against normal keratinocytes, which makes them promising candidates for 
antibacterial drugs.  
The reported compounds were also tested for activity against three fungal strains: C. albicans, S. 
cerevisae and A. brasiliensis. Of all the compounds 3c and 3f showed the most potent and the 
broadest activity versus all three strains, significantly higher than nystatin. Interesting behaviour 
was noted for regioisomeric pairs 3c-4c and 3f-4f. Pair 3c-4c displayed the same activity toward 
C. albicans and S. cerevisae but 3c was much more active against A. brasiliensis. On the other 
hand, 3f-4f pair showed the same activity toward A. brasiliensis, with 3f being much more active 
against the other two strains. 3-Substituted compounds generally showed a stronger activity than 
their 4-substituted counterparts. Avarone derivatives again showed a low activity, with their MIC 
values falling beyond the concentration range used in the assay. Besides that, the structure 
requirements were not as clear-cut as for the antibacterial activity.  
 
Conclusion. 
Some general conclusions can be made regarding the optimization of scaffold structure, position 
and nature of substituents. Most importantly, tert-butyl derivatives showed at least the same or 
better cytotoxic activity and selectivity as avarone counterparts. This is if great importance in 
view of the availability of the precursor compound. 
2,6-Disubstituted quinones were shown to be more active than the corresponding 2,5-
disubstituted quinones in both series of compounds, due to differences in redox status. Selectivity 
to MDR cell line occurred with medium sized or longer alkylamino as well as with aralkylamino 
substituents. The most promising derivatives are 2-tert-butyl-6-(octylamino)-1,4-benzoquinone 
and 2-tert-butyl-6-(phenethylamino)-1,4-benzoquinone, because of their selectivity towards both 
sensitive and MDR cancer cells in comparison with normal cells  confirmed on several different 
levels: apoptosis, changes in redox balance and loss of mitochondrial membrane potential. 
Since several compounds showed a good selectivity to MDR cells, the results of this study might 
contribute to selecting candidates for overcoming the problem of multidrug resistance in cancer 
cells.  
EXPERIMENTAL SECTION 
General procedure. Reagents and solvents were obtained from commercial sources (Fluka, 
Sigma-Aldrich, Merck, Acros Organics). Solvents were distilled before use, while the other 
chemicals were used as received. All of the reactions were carried out under a normal atmosphere 
with magnetic stirring unless stated otherwise. The compounds were visualized under UV light 
(254 nm). Column chromatography was performed on silica gel with pore size 60 Å, 70-230 
mesh, 63-200 μm particle size, with the indicated solvents. Preparative thin-layer 
chromatography was performed on silica gel GF254 (with UV active indicator). The yields refer to 
purified products. 
1
H NMR spectra were recorded at on Varian Gemini 2000 200 MHz 
instrument and Bruker Avance III 500 MHz instrument. Measurements were made at temperature 
298 K and are reported in ppm using tetramethylsilane as internal standard (CDCl3 at 7.26 ppm). 
The coupling constants (J) are given in Hz, and the splitting patterns are designated as s, singlet; 
bs, broad singlet; d, doublet; dd, double doublet; t, triplet; m, multiplet. 
13
C NMR spectra were 
recorded on Varian Gemini 2000 200 MHz instrument and Bruker Avance III 500 MHz 
instrument. Measurements were made at temperature 298 K and are reported in ppm using 
tetramethylsilane as internal standard (CDCl3 at 77.0 ppm). All mass spectra were recorded using 
electrospray ionisation. Optical rotations were measured on a Rudolph Research Analytical 
Autopol IV polarimeter. UV–Vis spectra were recorded using Cintra 40  UV–Visible 
spectrometer. 
tert-Butyl-1,4-benzoquinone (1). tert-Butylhydroquinone (2 g; 12 mmol) was dissolved in 
diethyl ether (100 mL). Silver(I) oxide  (3.74 g; 16.14 mmol) was added in portions to the 
reaction mixture, and the mixture was stirred for 2 hours at room temperature. After this period 
stirring was stopped, sodium sulphate was added and the  mixture was left overnight. Silver, 
excess of silver(I) oxide and sodium sulphate were removed by filtration over Kieselgur. Diethyl 
ether was removed by evaporation and tert-butyl-1,4-benzoquinone used without further 
purification. The reaction yield was quantitative. 
Avarone (2). Avarol (1.1 g; 3.5 mmol) was dissolved in diethyl ether (100 mL). Silver(I) oxide 
(1.1 g; 4.7 mmol) was added in portions to the reaction mixture, and the mixture was stirred for 2 
h at room temperature. The reaction mixture work-up was the same as above. The reaction yield 
was quantitative. 
General synthetic procedure. Quinones (300mg, unless stated otherwise; 1.83 mmol 1; 0.96 
mmol 2) were dissolved in ethanol (50 mL). Hydrochloride salts (in large excess; 22.22 mmol for 
1; 21.12 mmol for 2, unless stated otherwise) were prepared from alkyl and aralkyl amines as 
aqueous solutions if amines were soluble in water, or solutions in mixture of water and ethanol if 
amines were not soluble in water. pH of the solution was adjusted to pH 7–8 by adding solid 
sodium bicarbonate, and added into solution of a quinone. Water and ethanol were added to the 
reaction mixture to the final ratio water–ethanol (1:1, 300 mL). Reaction mixture was stirred at 
room temperature for 16 h. Ethanol was removed by vacuum evaporation, and the reaction 
mixture was extracted by methylene chloride, two times with half the volume of the water. 
Organic phase was separated, dried with anhydrous calcium chloride, and the solvent removed by 
evaporation under vacuum. Crude products were separated by column chromatography and 
purified by preparative thin-layer chromatography, with the indicated solvents. 
2-tert-butyl-6-(methylamino)-1,4-benzoquinone (3a). The compound was separated from its 
regioisomer by column chromatography using toluene–ethyl acetate (9:1) as eluent and purified 
by preparative thin layer chromatography using toluene–ethyl acetate (9:1) as eluent (Rf = 0.24). 
The product was obtained as reddish brown crystal, m.p. 178
0
C. Yield 105 mg; 59.5 %. 
1
H NMR (500 MHz, CDCl3)  δ 1.26 (s, 9H, C2-C(CH3)3), 2.85 (d, J = 5.5 Hz, 3H, C6-NHCH3), 
5.41 (d, J = 2 Hz, 1H, C5-H ), 5.79 (bs, 1H, C6-NHCH3) 6.47 (d, J = 2.5 Hz 1H, C3-H).  
13
C NMR (125 MHz, CDCl3) δ 29.0 (3C, C2-C(CH3)3) 29.2 (1C, C6-NHCH3) 34.7 (1C, C2-
C(CH3)3), 96.7 (1C, C5), 135.0 (1C, C3), 148.6 (1C, C6), 151.2 (1C, C2), 183.1 (1C, C1) 186.0 
(1C, C4). IR (ATR) 3310.7 3070.8 3003.1 2962.9 2921.9 2874.1 2803.2 1674.7 1625.9 1575.2 
1499.9 1449.2 1411.6 1373.8 1339.6 1261.1 1206.6 1176.5 1138,6 1068.4 907.1 796.1 cm
-1
. 








). MS C11H15NO2, exact 
mass = 193.1103, [M+H]
+
, calculated m/z = 194.11756; found 194.11742. Ec1 = –1.200 V; Ea1 = 
–1.104 V; Ec2 = –1.910 V; Ea2 = –1.785 V; E°1/Fc = –1.213 V. 
2-tert-Butyl-5-(methylamino)-1,4-benzoquinone (4a). The compound was separated from its 
regioisomer by column chromatography using toluene–ethyl acetate (9:1) as eluent and purified 
by preparative thin layer chromatography using toluene–ethyl acetate (9:1) as eluent (Rf = 0.46). 
The product was obtained as reddish brown crystal, m.p. 94
0
C. Yield 8.9 mg; 5.0 %. 
1
H NMR 
(500 MHz, CDCl3) δ 1.30 (s, 9H, C2-C(CH3)3 ), 2.82 (d, J = 5 Hz, 3H, C5-NHCH3) 5.38 (s, 1H, 
C6-H), 5.44 (bs, 1H, C5-NHCH3), 6.43 (s, 1H, C3-H). 
13
C NMR (125 MHz, CDCl3) δ 28.9 (1C, 
C5-NHCH3), 29.7 (3C, C2-C(CH3)3), 35.7 (1C, C2-C(CH3)3), 100.2 (1C, C6), 127.4 (1C, C3), 
146.3 (1C, C5), 159.7 (1C, C2), 184.8 (1C, C4), 185.8 (1C, C1). IR (ATR) 3302.6 3069.1 3007.3 
2959.5 2914.6 2816.9 1669.9 1621.3 1578.5 1504.2 1458.1 1420.1 1342.8 1240.7 1195.1 1148.6 
1060.0 1023.1 885.0 832.2 cm
-1









). MS: C11H15NO2, exact mass = 193.1103; [M+H]
+
, calculated m/z = 194.11756; found 
194.11785. Ec1 = –1.200 V, Ea1 = –1.124 V, Ec2 = –1.906 V, Ea2 = –1.766 V, E°1/Fc = –1.223 V. 
2-tert-Butyl-6-(ethylamino)-1,4-benzoquinone (3b). The compound was separated from its 
regioisomer by column chromatography using toluene–ethyl acetate (9:1) as eluent (Rf = 0.32) 
and purified by preparative thin layer chromatography using hexane–acetone (8:2) as eluent (Rf = 
0.43). The product was obtained as reddish brown oil. Yield 10.2 mg; 5.3 %. 
1
H NMR (500 MHz, 
CDCl3) δ 1.26 (s, 9H, C2-C(CH3)3), 1.29 (t, J = 7 Hz, 3H, C2’-H3), 3.14 (quintet, J = 7 Hz, 2H, 
C1’-H2), 5.42 (d, J = 2 Hz, 1H, C5-H), 5.64 (bs, 1H, C6-NHEt), 6.46 (d, J = 2 Hz, 1H, C3-
H).
13
C NMR (125 MHz, CDCl3) δ 13.4 (C2’), 29.0 (3C, C2-C(CH3)3), 34.7 (1C, C2-C(CH3)3), 
37.3 (C1’), 97.0 (C5), 135.0 (C3), 147.4 (C6), 151.2 (C2), 183.2 (C1), 186.1 (C4). IR (ATR) 
3386.0 3320.5 2962.3 2871.9 1729.3 1670.7 1631.5 1584.7 1506.5 1466.8 1362.3 1338.0 1257.5 
1169.9 1095.0 1062.9 907.4 804.4 cm
-1









). MS C12H17NO2, exact mass = 207.1259 [M+H]
+
, calculated m/z = 
208.13321, found 208.13318, [2M+H]
+
, calculated m/z = 415.25913, found 415.25877. Ec1 = –
1.160 V, Ea1 = –1.080 V, Ec2 = –1.896 V, Ea2 = –1.746 V, E°1/Fc = –1.191 V. 
2-tert-Butyl-5-(ethylamino)-1,4-benzoquinone (4b). The compound was separated from its 
regioisomer by column chromatography using toluene–ethyl acetate (9:1) as eluent (Rf = 0.54) 
and purified by preparative thin layer chromatography using hexane–acetone (8:2) as eluent (Rf = 
0.58). The product was obtained as reddish brown crystal, m.p. 136
0
C. Yield 4.5 mg; 2.4 %.  
1
H NMR (500 MHz, CDCl3) δ 1.27 (t, J = 7 Hz, 3H, C2’-H3), 1.30 (s, 9H, C2-C(CH3)3), 3.11 
(quintet, J = 7 Hz, 2H, C1’-H2), 5.34 (bs, 1H, C5-NHEt), 5.38 (s, 1H, C6-H), 6.43 (s, 1H, C3-H). 
13
C NMR (125 MHz, CDCl3) δ 13.5 (C2’), 29.7 (3C, C2-C(CH3)3), 35.7 (C2-C(CH3)3), 37.0 
(C1’), 100.4 (C6), 127.4 (C3), 145.2 (C5), 159.7 (C2), 184.8 (C4), 185.9 (C1). IR (ATR) 3391.6 
3057.3 2962.3 1669.7 1644.4 1625.9 1590.6 1513.3 1475.6 1364.1 1265.7 1221.2 1183.8 1108.3 
1018.1 894.2 865.0 831.9 739.2 cm
-1









). MS C12H17NO2, exact mass = 207.1259 [M+H]
+
, calculated m/z = 208.13321, 
found 208.13342; Ec1 = –1.170 V, Ea1 = –1.102 V, Ec2 = –1.860 V,  Ea2 = –1.672 V E°1/Fc = –
1.211 V. 
2-tert-Butyl-6-(butylamino)-1,4-benzoquinone (3c). The compound was synthesized by 
reaction of 1,4-benzoquinone 1 (312 mg, 1.9 mmol) with n-butylamine(1.68 g, 2.28 mL, 23 
mmol). It was separated from its regioisomer by column chromatography using toluene–ethyl 
acetate (9:1) as eluent and purified by preparative thin layer chromatography using toluene-
ethylacetate (9:1) as eluent (Rf = 0.44). The product was obtained as reddish brown oil. Yield 
124.9 mg; 55.9 %. 
1
H NMR (500 MHz, CDCl3) δ 0.96 (t, J = 3 Hz, 3H, C4’-H3), 1.26 ( s, 9H, 
C2-C(CH3)3), 1.42 (sextet, J = 3 Hz, 2H, C3’-H2), 1.64 (quintet, J = 3 Hz, 2H, C2’-H2), 3.08 (q, J 
= 2.8 Hz, 2H, C1’-H2), 5.42 (d, J = 2.5 Hz, 1H, C5-H), 5.69 (bs, 1H, C6-NH
n
Bu), 6.46 (d, J = 2.5 
Hz, 1H, C3-H). 
13
C NMR (125 MHz, CDCl3) δ 13.7 (1C, C4’), 20.2 (1C, C3’), 29.0 (3C, C2-
C(CH3)3), 30.2 (1C, C2’), 34.7 (1C, C2-C(CH3)3), 42.3 (1C, C1’), 97.0 (1C, C5), 135.1 (1C, C3), 
147.6 (1C, C6), 151.2 (1C, C2), 183.2 (1C, C1), 186.0 (1C, C4). IR (ATR) 3387.2 3302.5 2993.1 
2959.9 2932.2 2871.0 2363.4 1670.3 1632.4 1586.0 1506.9 1465.7 1363.2 1338.8 1255.9 1206.4 
1164.9 1075.9 964.9 905.5 807.1 cm
-1









). MS C14H21NO2, exact mass = 235.1572 [M+H]
+
, calculated m/z = 
236.16451 found 236.16460. Ec1 = –1.160 V, Ea1 = –1.081 V, Ec2 = –1.892 V, Ea2 = –1.759 V, 
E°1/Fc = –1.192 V. 
2-tert-Butyl-5-(butylamino)-1,4-benzoquinone (4c). The compound was synthesized by 
reaction of 1,4-benzoquinone 1 (312 mg, 1.9 mmol) with n-butylamine (1.68 g, 2.28 mL, 23 
mmol). It was separated from its regioisomer by column chromatography using toluene–ethyl 
acetate (9:1) as eluent and purified by preparative thin layer chromatography using toluene–ethyl 
acetate (9:1) as eluent (Rf = 0.70). The product was obtained as reddish brown crystal, m.p. 59
0
C. 
Yield 28.7 mg; 12.8 %. 
1
H NMR (500 MHz, CDCl3) δ 0.95 (t, J = 3 Hz, 3H, C4’-H3), 1.30 (s, 
9H, C2-C(CH3)3), 1.40 (sextet, J = 3 Hz, 2H, C3’-H2), 1.61 (quintet, J = 3 Hz, 2H, C2’-H2), 3.06 
(q, J = 2.6 Hz, 2H, C1’-H2), 5.38 (s, 2H, C4-NH
n
Bu, C6-H), 6.43 (s, 1H, C3-H). 
13
C NMR (125 
MHz, CDCl3) δ 13.7 (1C, C4’), 20.2 (1C, C3’), 29.7 (3C, C2-C(CH3)3), 30.3 (1C, C3’), 35.7 
(1C, C2-C(CH3)3), 42.0 (1C, C1’), 100.3 (1C, C6), 127.4 (1C, C3), 145.4 (1C, C5), 159.7 (1C, 
C2), 184.9 (1C, C4), 185.8 (1C, C1). IR (ATR) 3734.1 3294.1 3081.5 3003.2 2958.7 2929.5 
2869.7 2195.6 2156.3 2025.5 1970.3 1671.7 1624.5 1578.0 1509.8 1459.3 1349.3 1297.6 1237.7 
1191.0 1066.0 1015.8 893.5 841.2 672.0 cm
-1









). MS C14H21NO2, exact mass = 235.1572 [M+H]
+
, calculated m/z = 
236.16451, found 236.16462, [2M+H]
+
, calculated m/z = 474.32173, found 474.32154. 
Ec1 = –1.182 V, Ea1 = –1.096 V, Ec2 = –1.921 V, Ea2 = –1.773 V, E°1/Fc = –1.210 V. 
2-tert-Butyl-6-(octylamino)-1,4-benzoquinone (3d). The compound was separated from its 
regioisomer by column chromatography using toluene–ethyl acetate (9:1) as eluent and purified 
by preparative thin layer chromatography using toluene–ethyl acetate (9:1) as eluent (Rf = 0.56). 
The product was obtained as reddish brown oil. Yield 138.5 mg; 52.0 %. 
1
H NMR (500 MHz, 
CDCl3) δ 0.89 (t, J = 2.8 Hz, 3H, C8’-H3), 1.26 (m, 19H), 1.64 (quintet, J = 3 Hz, 2H, C2’-H2), 
3.07 (q, J = 2.8 Hz, 2H, C1’-H2), 5.41 (d, J = 2.5 Hz, 1H, C5-H), 5.70 (bs, 1H, C5-NH
n
Oct), 6.46 
(d, J = 2.5 Hz, 1H, C3-H). 
13
C NMR (125 MHz, CDCl3) δ 14.0 (1C, C8’), 22.6 (1C, C7’), 27.0 
(1C, C3’), 28.2 (1C, C2’/C6’), 29.0 (3C, C2-C(CH3)3), 29.1 (1C, C4’/C5’), 29.2 (1C, C4’/C5’), 
31.7 (1C, C2’/C6’), 34.7 (1C, C2-C(CH3)3), 42.6 (1C, C1’), 97.0 (1C, C5), 135.1 (1C, C3), 
147.5 (1C, C6), 151.2 (1C, C2), 183.2 (1C, C1), 186.0 (1C, C4). IR (ATR) 3390.5 3295.0 2957.4 
2927.3 2856.5 1669.7 1631.8 1585.7 1506.4 1465.0 1362.9 1338.9 1255.8 1160.4 1074.0 906.4 
807.2 cm
-1









MS C18H29NO2, exact mass = 291.2198 [M+H]
+
, calculated m/z = 292.22711, found 292.22811, 
[2M+H]
+
, calculated m/z = 583.44693, found 583.44804. Ec1 = –1.183 V, Ea1 = –1.095 V, Ec2 = –
1.917 V, Ea2 = –1.806 V, E°1/Fc = –1.200 V. 
2-tert-Butyl-5-(octylamino)-1,4-benzoquinone (4d). The compound was separated from its 
regioisomer by column chromatography using toluene–ethyl acetate (9:1) as eluent and purified 
by preparative thin layer chromatography using toluene–ethyl acetate (9:1) as eluent (Rf = 0.76). 
The product was obtained as reddish brown oil. Yield 25.0 mg; 9.4 %. 
1
H NMR (500 MHz, 
CDCl3)  δ 0.88 (t, J = 3 Hz, 3H, C8’-H3), 1.30 (m, 19H), 1.62 (quintet, J = 2.8 Hz, 2H, C2’-H2), 
3.05 (q, J = 2.8 Hz, 2H, C1’-H2), 5.38 (s, 1H, C6-H), 5.40 (bs, 1H, C5-NH
n
Oct ); 6.43 (s, 1H, 
C3-H). 
13
C NMR (125 MHz, CDCl3) δ 14.0 (1C, C8’), 22.6 (1C, C7’), 27.0 (1C, C3’), 28.2 (1C, 
C2’/C6’), 29.1 (1C, C4’/C5’), 29.2 (1C, C4’/C5’), 29.7 (3C, C2-C(CH3)3), 31.7 (1C, C2’/C6’), 
35.7 (1C, C2-C(CH3)3), 42.3 (1C, C1’), 100.2 (1C, C6), 127.4 (1C, C3), 145.3 (1C, C5), 159.7 
(1C, C2), 184.9 (1C, C4), 185.8 (1C, C1). IR (ATR) 3392.8 2925.6 2856.0 1735.9 1669.2 1625.9 
1587.4 1514.1 1462.0 1364.7 1338.1 1226.9 1187.8 1019.9 952.4 798.3 cm
-1









). MS C18H29NO2, exact mass = 291.2198 
[M+H]
+
, calculated m/z = 292.22711, found 292.22813. Ec1 = –1.199 V, Ea1 = –1.116 V, Ec2 = –
1.933 V, Ea2 = –1.785 V, E°1/Fc = –1.219 V. 
2-(Benzylamino)-6-(tert-butyl)-1,4-benzoquinone (3e). The compound was synthesized by 
reaction of 1,4-benzoquinone 1 (300 mg, 1.83 mmol) with benzylamine (4.3 g, 4.4 mL, 40.2 
mmol). It was separated from its regioisomer by column chromatography using toluene–ethyl 
acetate (9:1) as eluent (Rf = 0.39)  and purified by preparative thin layer chromatography using 
hexane–acetone (8:2) as eluent (Rf = 0.41). The product was obtained as reddish brown crystal, 
m.p. 132
0
C. Yield 102.1 mg; 41.5 %. 
1
H NMR (200 MHz, CDCl3) δ 1.27 (s, 9H, C6-C(CH3)3), 
4.26 (d, J = 4 Hz, 2H, C1’-H2), 5.48 (d, J = 2 Hz, 1H, C3-H), 6.01 (bs, 1H, C2-NHCH2Ph), 6.46 
(d, J = 2 Hz, 1H, C5-H), 7.32 (m, 5H, C3’-H, C4’-H, C5’-H, C6’-H, C7’-H). 
13
C NMR (50 
MHz, CDCl3) δ 29.0 (3C, C6-C(CH3)3), 34.8 (1C, C6-C(CH3)3), 46.9 (1C, C1’), 98.0 (1C, C3), 
127.7 (2C, C3’, C7’), 128.1 (1C, C5’), 129.0 (2C, C4’, C6’), 134.8 (1C, C5), 136.0 (1C, C2’), 
147.3 (1C, C2), 151.4 (1C, C6), 183.2 (1C, C1), 186.2 (1C, C4). IR (ATR) 3566.5 3511.2 3362.5 
3199.2 3063.5 3031.6 2998.8 2965.5 2873.6 1671.8 1634.9 1587.5 1504.2 1456.7 1364.2 1340.1 
1257.8 1163.4 1061.1 909.6 cm
-1









). MS C17H19NO2, exact mass = 269.1416 [M+H]
+
, calculated m/z = 270.14886, found 
270.14903, [2M+H]
+
, calculated m/z = 539.29043, found 539.28999. Ec1 = –1.128 V, Ea1 = –
1.053 V, Ec1 = –1.800 V, Ea2 = –1.619 V, E°1/Fc = –1.159 V. 
2-(Benzylamino)-5-(tert-butyl)1,4-benzoquinone (4e). The compound was synthesized by 
reaction of 1,4-benzoquinone 1 (300 mg, 1.83 mmol) with benzylamine (4.3 g, 4.4 mL, 40.2 
mmol). It was separated from its regioisomer by column chromatography using toluene–ethyl 
acetate (9:1) as eluent (Rf = 0.51) and purified by preparative thin layer chromatography using 
hexane–acetone (8:2) as eluent (Rf = 0.49). The product was obtained as reddish brown oil. Yield 
17.1 mg; 7.0 %. 
1
H NMR (200 MHz, CDCl3) δ 1.29 (s, 9H, C5-C(CH3)3), 4.26 (d, J = 6 Hz, 2H, 
C1’-H2), 5.45 (s, 1H, C3-H), 5.74 (bs, 1H, C2-NHCH2Ph), 6.45 (s, 1H, C6-H), 7.32 (m, 5H,C3’-
H, C4’-H, C5’-H, C6’-H, C7’-H). 
13
C NMR (50 MHz, CDCl3) δ 29.6 (3C, C5-C(CH3)3), 35.7 
(1C, C5-C(CH3)3), 46.6 (1C, C1’), 101.2 (1C, C3), 127.5 (1C, C5’), 127.6 (2C, C3’, C7’), 128.0 
(1C, C6), 128.9  (2C, C4’, C6’), 136.1 (1C, C2’), 145.1 (1C, C2), 159.5 (1C, C5), 184.8 (1C, 
C1), 186.0 (1C, C4). IR (ATR) 3384.0 3061.9 3029.6 3003.0 2960.7 2920.8 2868.3 1668.5 
1626.6 1587.3 1513.4 1455.3 1389.0 1360.7 1337.5 1229.2 1182.8 1062.3 1021.6 895.4 836.0 
803.8 741.1 700.4 cm
-1









). MS C17H19NO2, exact mass = 269.1416 [M+H]
+
, calculated m/z = 270.14886, found 
270.14910. Ec1 = –1.141 V, Ea1 = –1.071 V, Ec2 = –1.803 V, Ea2 = –1.593 V, E°1/Fc = –1.174 V. 
2-(tert-Butyl)-6-(phenethylamino)-1,4-benzoquinone (3f). The compound was synthesized by 
reaction of 1,4-benzoquinone 1 (300 mg, 1.83 mmol) with phenethylamine (4.87 g, 5.05 mL, 40.2 
mmol). It was separated from its regioisomer by column chromatography using toluene–ethyl 
acetate (9:1) as eluent (Rf = 0.38) and purified by preparative thin layer chromatography using 
hexane–acetone (7:3) as eluent (Rf = 0.44). The product was obtained as reddish brown oil. Yield 
91.9 mg; 35.5 %. 
1
H NMR (200 MHz, CDCl3) δ 1.26 (s, 9H,C2-C(CH3)3), 2.94 (t, J = 7 Hz, 2H, 
C2’-H), 3.35 (q, J = 7 Hz, 2H, C1’-H2), 5.47 (d, J = 3 Hz, 1H, C5-H), 5.76 (bs, 1H, C6-
NHCH2CH2Ph), 6.45 (d, J = 3 Hz, 1H, C3-H), 7.22-7.34 (m, 5H, {C4’-C8’}-H). 
13
C NMR (50 
MHz, CDCl3) δ 28.9 (3C, C2-C(CH3)3), 34.3 (1C, C2-C(CH3)3), 34.7 (1C, C2’), 43.7 (1C, C1’), 
97.3 (1C, C5), 126.9 (1C, C6’), 128.6 (2C, C4’, C8’), 128.9 (2C, C5’, C7’), 134.9 (1C, C3), 
137.8 (1C, C3’), 147.3 (1C, C6), 151.3 (1C, C2), 183.1 (1C, C1), 186.1 (1C, C4). IR (ATR) 
3378.8 3304.2 3062.4 3027.5 2961.2 2870.6 1669.4 1632.6 1585.9 1505.4 1461.8 1362.7 1339.1 
1255.5 1196.7 1157.0 905.4 700.9 cm
-1









). MS C18H21NO2, exact mass = 283.1572 [M+H]
+
, calculated m/z = 
284.16451, found 284.16454, [2M+H]
+
, calculated m/z = 567.32173, found 567.32097. 
Ec1 = –1.135 V, Ea1 = –1.069 V, Ec2 = –1.889 V, Ea2 = –1.749 V, E°1/Fc = –1.174 V. 
2-(tert-Butyl)-5-(phenethylamino)-1,4-benzoquinone (4f). The compound was synthesized by 
reaction of 1,4-benzoquinone 1 (300 mg, 1.83 mmol) with phenethylamine (4.87 g, 5.05 mL, 40.2 
mmol). It was separated from its regioisomer by column chromatography using toluene–ethyl 
acetate (9:1) as eluent (Rf = 0.62) and purified by preparative thin layer chromatography using 
hexane–acetone (7:3) as eluent (Rf = 0.51). The product was obtained as reddish brown crystal, 
m.p. 100
0
C. Yield 21.0 mg; 8.1 %. 
1
H NMR (200 MHz, CDCl3) δ 1.30 (s, 9H, C2-C(CH3)3), 2.91 
(t, J = 6.8 Hz, 2H, C2’-H2), 3.34 (q, J = 6.6 Hz, 2H, C1’-H2), 5.44 (s, 1H, C6-H), 5.46 (bs, 1H, 
C5-NHCH2CH2Ph), 6.42 (s, 1H, C3-H), 7.17-7.37 (m, 5H, {C4’-C8’}-H).  
13
C NMR (50 MHz, CDCl3) δ 29.6 (3C, C2-C(CH3)3), 34.3 (1C,  C2-C(CH3)3), 35.7 (1C, C2’), 
43.4 (1C, C1’), 100.6 (1C, C6), 126.9 (1C, C6’), 127.5 (1C, C3), 128.6 (2C, C4’, C8’), 128.8 
(2C, C5’, C7’), 137.9 (1C, C3’), 145.1 (1C, C5), 159.6 (1C, C2), 184.7 (1C, C4), 185.9 (1C, 
C1). IR (ATR) 3278.2 3065.1 3029.6 3005.1 2959.5 2871.0 1670.7 1622.8 1583.3 1508.1 1455.9 
1360.2 1284.0 1236.5 1197.8 1068.2 1021.3 895.2 841.4 749.3 699.6 cm
-1









). MS C18H21NO2, exact mass = 283.1572 
[M+H]
+
, calculated m/z = 284.16451, found 284.16424. Ec1 = –1.147 V, Ea1 = –1.084 V, Ec2 = –
1.873 V, Ea2 = –1.728 V, E°1/Fc = –1.188 V. 
2-(Butylamino)-6-(((1R,2S,4aS,8aS)-1,2,4a,5-tetramethyl-1,2,3,4,4a,7,8,8a-
octahydronaphthalen-1-yl)methyl)cyclohexa-2,5-diene-1,4-dione (3g). The compound was 
synthesized by reaction of avarone 2 (220 mg, 0.705 mmol) with n-butylamine (1.13 g, 1.54 mL, 
15.51 mmol). It was separated from its regioisomer by column chromatography using toluene–
ethyl acetate (9:1) as eluent and purified by preparative thin layer chromatography using toluene–
ethyl acetate (9:1) as eluent (Rf = 0.40). The product was obtained as reddish brown oil. Yield 
41.6 mg; 30.8 %. 
1
H NMR (200 MHz, CDCl3) δ 0.80-1.10 (m, 9H, C4’’-H3, C13-H3, C14-H3), 
1.20-1.70 (m, 16H, C1-H2, C7-H2, C8-H, C10-H, C11-H3, C12-H3, C2’’-H2, C3’’-H2), 1.80-2.20 
(m, 4H, C2-H2, C6-H2), 2.37 (d, J = 13.4 Hz, 1H, C15-Ha), 2.62 (d, J = 13.4 Hz, 1H, C15-Hb), 
3.07 (dd, 2H, C1’’-H2), 5.14 (s, 1H, C3-H), 5.42 (d, J = 2.2 Hz, 1H, C4’-H), 5.63 (bs, 1H, C3’N-
H), 6.37 (d, J = 2.2 Hz, 1H, C6’-H). 
13
C NMR (50 MHz, CDCl3) δ 13.7 (1C, C4’’), 16.6 (1C, 
C13), 17.7 (1C, C14), 18.0 (1C, C11), 19.3 (1C, C12), 20.0 (1C, C1), 20.1 (1C, C3’’), 26.5 (1C, 
C2), 27.3 (1C, C7), 30.1 (1C, C2’’), 34.9 (1C, C15), 35.9 (1C, C6), 36.5 (1C, C8), 38.4 (1C, 
C9), 42.0 (1C, C5), 42.3 (1C, C1’’), 46.7 (1C, C10), 97.6 (1C, C4’), 120.6 (1C, C3), 139.9 (1C, 
C6’), 142.0 (1C, C1’), 144.0 (1C, C4), 146.8 (1C, C3’), 184.0 (1C, C2’), 185.5 (1C, C5’). IR 
(ATR) 3389.7 3301.5 2958.9 2931.8 2870.2 1671.4 1635.4 1588.0 1508.1 1464.5 1380.1 1346.8 
1287.9 1250.3 1190.5 1124.5 1090.0 1040.6 914.5 802.1 737.7 cm
-1









). MS C25H37NO2, exact mass = 383.2824 [M+H]
+
, 
calculated m/z = 384.28971, found 384.28892, [2M+H]
+
, calculated m/z = 767.57214, found 
767.57256. Ec1 = –1.138 V, Ea1 = –1.067 V, Ec2 = –1.876 V, Ea2 = –1.747 V, E°1/Fc = –1.172 V. 
[α]
20 
= –40º (c = 0.083 in MeOH). 
2-(Butylamino)-5-(((1R,2S,4aS,8aS)-1,2,4a,5-tetramethyl-1,2,3,4,4a,7,8,8a-
octahydronaphthalen-1-yl)methyl)cyclohexa-2,5-diene-1,4-dione (4g). The compound was 
synthesized by reaction of avarone 2 (220 mg, 0.705 mmol) with n-butylamine (1.13 g, 1.54 mL, 
15.51 mmol). It was separated from its regioisomer by column chromatography using toluene–
ethyl acetate (9:1) as eluent and purified by preparative thin layer chromatography using toluene–
ethyl acetate (9:1) as eluent (Rf = 0.60). The product was obtained as reddish brown oil. Yield 
17.0 mg; 12.6 %. 
1
H NMR (200 MHz, CDCl3) δ 0.80-1.10 (m, 9H, C4’’-H3, C13-H3, C14-H3), 
1.20-1.70 (m, 16H, C1-H2, C7-H2, C8-H, C10-H, C11-H3, C12-H3, C2’’-H2, C3’’-H2), 1.80-2.20 
(m, 4H, C2-H2, C6-H2), 2.46 (d, 1H, C15-Ha), 2.65 (d, 1H, C15-Hb), 3.07 (dd, 2H, C1’’-H2), 
5.15 (s, 1H, C3-H), 5.43 (s, 1H, C3’-H), 5.51 (bs, 1H, C4’N-H), 6.36 (s, 1H, C6’-H).  
13
C NMR (50 MHz, CDCl3) δ 13.6 (1C, C4’’), 16.8 (1C, C13) 17.8 (1C, C14) 18.0 (1C, C11), 
19.4(1C, C12), 20.0 (1C, C1), 20.1 (1C, C3’’), 26.5 (1C, C2), 27.5 (1C, C7), 30.2 (1C, C2’’), 
35.7 (1C, C15), 36.1 (1C, C6), 37.0 (1C, C8), 38.5 (1C, C9), 42.0 (1C, C5), 43.1 (1C, C1’’), 
47.2 (1C, C10), 98.2 ( 1C, C3’), 120.8 (1C, C3), 131.7 (1C, C6’), 144.0 (1C, C1’), 146.1 (1C, 
C4), 151.3 (1C, C4’), 183.7 (1C, C5’), 185.2 (1C, C2’). IR (ATR) 3354.6 2959.1 2932.1 2868.3 
1665.5 1628.5 1593.4 1514.3 1463.3 1380.6 1318.2 1241.7 1222.4 1197.9 1130.0 1099.9 898.7 
842.9 cm
-1









C25H37NO2, exact mass = 383.2824 [M+H]
+
, calculated m/z = 384.28971, found 384.28848, 
[2M+H]
+
, calculated m/z = 767.57214, found 767.57067. Ec1 = –1.148 V, Ea1 = –1.078 V, Ec2 = –
1.888 V, Ea2 = –1.749 V, E°1/Fc = –1.182 V. [α]
20 
= 80º (c = 0.083 in MeOH). 
2-(Octylamino)-6-(((1R,2S,4aS,8aS)-1,2,4a,5-tetramethyl-1,2,3,4,4a,7,8,8a-
octahydronaphthalen-1-yl)methyl)cyclohexa-2,5-diene-1,4-dione (3h). The compound was 
separated from its regioisomer by column chromatography using toluene–ethyl acetate (9:1) as 
eluent and purified by preparative thin layer chromatography using toluene–ethyl acetate (9:1) as 
eluent (Rf = 0.57). The product was obtained as reddish brown oil. Yield 98.6 mg; 46.6 %. 
1
H NMR (200 MHz, CDCl3) δ 0.80-1.10 (m, 9H, C8’’-H3, C13-H3, C14-H3), 1.20-1.70 (m, 24H, 
C1-H2, C7-H2, C8-H, C10-H, C11-H3, C12-H3, C2’’-H2, C3’’-H2, C4’’-H2, C5’’-H2, C6’’-H2, 
C7’’-H2), 1.80-2.20 (m, 4H, C2-H2, C6-H2), 2.37 (d, J = 14 Hz, 1H, C15-Ha), 2.62 (d, J = 14 Hz, 
1H, C15-Hb), 3.06 (dd, 2H, C1’’-H2), 5.14 (s, 1H, C3-H), 5.41 (d, J = 2.2 Hz, 1H, C4’-H), 5.62 
(s, 1H, C3’N-H), 6.37 (d, J = 2.2 Hz, 1H, C6’-H). 
13
C NMR (50 MHz, CDCl3) δ 14.0 (1C, C8’’), 
16.6 (1C, C13), 17.7 (1C, C14), 18.0 (1C, C11), 19.3 (1C, C1), 20.0 (1C, C12), 22.6 (1C, C7’’), 
26.5 (1C, C2), 27.0 (1C, C3’’), 27.3 (1C, C7), 28.1 (1C, C4’’), 29.1 (1C, C5’’), 29.1 (1C, C2’’), 
31.7 (1C, C6’’), 34.9 (1C, C15), 35.9 (1C, C6), 36.5 (1C, C8), 38.4 (1C, C9), 42.0 (1C, C5), 
42.6 (1C, C1’’), 46.7 (1C, C10), 97.6 (1C, C4’), 120.6 (1C, C3), 139.9 (1C, C6’), 142.0 (1C, 
C1’), 144.0 (1C, C4), 146.8 (1C, C3’), 184.0 (1C, C2’), 185.5 (1C, C5’).  IR (ATR) 3390.2 
3314.7 2927.6 2856.3 1671.0 1635.4 1588.3 1507.5 1465.6 1345.7 1249.8 1193.0 cm
-1
. UV–Vis 








). MS C29H45NO2, exact mass = 
439.3450 [M+H]
+
, calculated m/z = 440.35231, found 440.35203, [2M+H]
+
, calculated m/z = 
879.69734, found 879.69826. Ec1 = –1.132 V, Ea1 = –1.059 V, Ec2 = –1.852 V, Ea2 = –1.711 V, 
E°1/Fc = –1.165 V. [α]
20 
= 10º (c = 0.083 in MeOH). 
2-(Octylamino)-5-(((1R,2S,4aS,8aS)-1,2,4a,5-tetramethyl-1,2,3,4,4a,7,8,8a-
octahydronaphthalen-1-yl)methyl)cyclohexa-2,5-diene-1,4-dione (4h). The compound was 
separated from its regioisomer by column chromatography using toluene–ethyl acetate (9:1) as 
eluent (Rf = 0.75) and purified by preparative thin layer chromatography using chloroform as 
eluent (Rf = 0.60). The product was obtained as reddish brown oil. Yield 46.6 mg; 22.0 %. 
1
H NMR (200 MHz, CDCl3) δ 0.80-1.10 (m, 9H, C8’’-H3, C13-H3, C14-H3), 1.20-1.70 (m, 24H, 
C1-H2, C7-H2, C8-H, C10-H, C11-H3, C12-H3, C2’’-H2, C3’’-H2, C4’’-H2, C5’’-H2, C6’’-H2, 
C7’’-H2), 1.80-2.20 (m, 4H, C2-H2, C6-H2), 2.46 (d, J = 13 Hz, 1H, C15-Ha), 2.65 (d, J = 13.6 
Hz, 1H, C15-Hb), 3.06 (dd, 2H, C1’’-H2), 5.15 (s, 1H, C3-H), 5.42 (s, 1H, C3’-H), 5.50 (bs, 1H, 
C4’N-H), 6.35 (s, 1H, C6’-H). 
13
C NMR (50 MHz, CDCl3) δ 14.0 (1C, C8’’), 16.8 (1C, C13), 
17.8 (1C, C14), 18.0 (1C, C11), 19.4 (1C, C1), 20.0 (1C, C12), 22.6 (1C, C7’’), 26.5 (1C, C2), 
27.0 (1C, C3’’), 27.5 (1C, C7), 28.2 (1C, C4’’), 29.1 (1C, C5’’), 29.2 (1C, C2’’), 31.7 (1C, 
C6’’), 35.7 (1C, C15), 36.1 (1C, C6), 37.0 (1C, C8), 38.5 (1C, C9), 42.3 (1C, C5), 43.1 (1C, 
C1’’), 47.2 (1C, C10), 98.2 (1C, C3’), 120.8 (1C, C3), 131.7 (1C, C6’), 144.0 (1C, C1’), 146.1 
(1C, C4), 151.3 (1C, C4’), 183.7 (1C, C5’), 185.2 (1C, C2’). IR (ATR) 3391.3 3359.3 2957.7 
2928.7 2857.1 1666.6 1628.9 1594.0 1512.7 1467.9 1382.4 1312.8 1221.6 cm
-1
. UV–Vis 








). MS C29H45NO2, exact mass = 
439.3450 [M+H]
+
, calculated m/z = 440.35231, found 440.35181, [2M+H]
+
, calculated m/z = 
879.69734, found 879.69842. Ec1 = –1.144 V, Ea1 = –1.076 V, Ec2 = –1.849 V, Ea2 = –1.684 V, 
E°1/Fc = –1.179 V. [α]
20 
= 50º (c = 0.083 in MeOH). 
2-(Phenethylamino)-6-(((1R,2S,4aS,8aS)-1,2,4a,5-tetramethyl-1,2,3,4,4a,7,8,8a-
octahydronaphthalen-1-yl)methyl)cyclohexa-2,5-diene-1,4-dione (3i). The compound was 
separated from regioisomer by column chromatography using toluene–ethyl acetate (9:1) as 
eluent (Rf = 0.58) and purified by preparative thin layer chromatography using hexane–acetone 
(8:2) as eluent (Rf = 0.38). The product was obtained as reddish brown oil. Yield 43.7 mg; 21.1 
%. 
1
H NMR (200 MHz, CDCl3) δ 0.80-1.10 (m, 6H, C13-H3, C14-H3), 1.20-1.80 (m, 12H, C1-
H2, C7-H2, C8-H, C10-H, C11-H3, C12-H3), 1.80-2.20 (m, 4H, C2-H2, C6-H2), 2.34 (d, J = 14 
Hz, 1H, C15-Ha), 2.63 (d, J = 14 Hz, 1H, C15-Hb), 2.92 (t, J = 7 Hz, 2H, C2’’-H2), 3.35 (dd, 
2H, C1’’-H2), 5.12 (s, 1H, C3-H), 5.46 (d, J = 2.4 Hz, 1H, C4’-H), 5.68 (bs, 1H, C3’N-H), 6.37 
(d, J = 2.4 Hz, 1H, C6’-H), 7.10-7.40 (m, 5H, C4’’-H, C5’’-H, C6’’-H, C7’’-H, C8’’-H). 
13
C NMR (50 MHz, CDCl3) δ 16.6 (1C, C13), 17.7 (1C, C14), 18.0 (1C, C11), 19.3 (1C, C1), 
20.0 (1C, C12), 26.5 (1C, C2), 27.3 (1C, C7), 34.2 (1C, C15), 35.9 (1C, C2’’), 36.0 (1C, C6), 
36.5 (1C, C8), 38.4 (1C, C9), 42.0 (1C, C5), 43.7 (1C, C1’’), 46.7 (1C, C10), 97.9 (1C, C4’), 
120.6 (1C, C3), 126.9 (1C, C6’’), 128.6 (2C, C4’’, C8’’), 128.8 (2C, C5’’, C7’’), 137.8 (1C, 
C3’’), 139.7 (1C, C6’), 142.2 (1C, C1’), 144.0 (1C, C4), 146.6 (1C, C3’), 183.8 (1C, C2’), 185.6 
(1C, C5’). IR (ATR) 3381.8 2931.7 1733.0 1671.1 1635.8 1587.9 1507.0 1456.9 1380.3 1347.2 
1253.4 1197.6 1096.4 1028.3 913.0 889.1 803.6 744.7 700.5 cm
-1









). MS C29H37NO2, exact mass = 431.2824 [M+H]
+
, 
calculated m/z = 432.28971, found 432.28613, [2M+H]
+
, calculated m/z = 863.57214, found 
863.56985. Ec1 = –1.123 V, Ea1 = –1.052 V, Ec2 = –1.876 V, Ea2 = –1.747 V, E°1/Fc = –1.156 V. 
[α]
20 
= 50º (c = 0.083 in MeOH). 
2-(Phenethylamino)-5-(((1R,2S,4aS,8aS)-1,2,4a,5-tetramethyl-1,2,3,4,4a,7,8,8a-
octahydronaphthalen-1-yl)methyl)cyclohexa-2,5-diene-1,4-dione (4i). The compound was 
separated from its regioisomer by column chromatography using toluene–ethyl acetate (9:1) as 
eluent (Rf = 0.76) and purified by preparative thin layer chromatography using hexane–acetone 
(8:2) as eluent (Rf = 0.49). The product was obtained as reddish brown crystal, m.p. 122-123
0
C. 
Yield 52.4 mg; 25.2 %. 
1
H NMR (200 MHz, CDCl3) δ 0.80-1.10 (m, 6H, C13-H3, C14-H3), 
1.20-1.80 (m, 12H, C1-H2, C7-H2, C8-H, C10-H, C11-H3, C12-H3), 1.80-2.20 (m, 4H, C2-H2, 
C6-H2), 2.46 (d, J = 13 Hz, 1H, C15-Ha), 2.65 (d, J = 13 Hz, 1H, C15-Hb), 2.93 (t, J = 7.4 Hz, 
2H, C2’’-H2), 3.35 (dd, 2H, C1’’-H2), 5.15 (s, 1H, C3-H), 5.47 (s, 1H, C3’-H), 5.57 (bs, 1H, 
C4’N-H), 6.35 (s, 1H, C6’-H), 7.10-7.40 (m, 5H, C4’’-H, C5’’-H, C6’’-H, C7’’-H, C8’’-H). 
13
C NMR (50 MHz, CDCl3) δ 16.8 (1C, C13), 17.7 (1C, C14), 18.0 (1C, C11), 19.3 (1C, C1), 
20.0 (1C, C12), 26.4 (1C, C2), 27.5 (1C, C7), 34.4 (1C, C15), 35.7 (1C, C2’’), 36.0 (1C, C6), 
37.0 (1C, C8), 38.5 (1C, C9), 43.1 (1C, C5), 43.4 (1C, C1’’), 47.1 (1C, C10), 98.5 (1C, C3’), 
120.7 (1C, C3), 126.9 (1C, C6’’), 128.6 (2C, C4’’; C8’’), 128.8 (2C, C5’’; C7’’), 131.8 (1C, 
C6’), 137.8 (1C, C3’’), 144.0 (1C, C1’), 145.8 (1C, C4), 151.2 (1C, C4’), 183.4 (1C, C5’), 185.3 
(1C, C2’). IR (ATR) 3360.9 2932.4 2361.1 1666.3 1628.8 1592.8 1513.6 1454.4 1380.1 1317.6 
1248.3 1221.8 1098.8 1032.4 898.8 800.1 747.2 700.8 cm
-1









). MS C29H37NO2, exact mass = 431.2824 [M+H]
+
, 
calculated m/z = 432.28971, found 432.29161, [2M+H]
+
, calculated m/z = 863.57214, found 
863.57121. Ec1 = –1.131 V, Ea1 = –1.061 V, Ec2 = –1.869 V, Ea2 = –1.729 V, E°1/Fc = –1.164 V. 
[α]
20 
= 40º (c = 0.083 in MeOH). 
Cyclic voltammetry. Cyclic voltammetry experiments were performed at room temperature 
under nitrogen atmosphere in a three-electrode cell at 25°C and using a CHI1760B workstation 
(CH Instruments, Austin TX, USA). The working electrode was glassy carbon disk (3mm 
diameter). The counter electrode was a platinum wire, and a silver wire immersed in electrolyte 
solution containing 0.01 M silver ions was used as the reference electrode. The quinone 
derivatives were used as 2 mM solution in dimethyl sulfoxide, with 0.1 M tetrabutylammonium 
perchlorate as an electrolyte. Ferrocene was used as reference compound. 
Biology. 
Anticancer activity. Chemicals. RPMI 1640 medium, DMEM medium, penicillin–streptomycin 
solution, antibiotic–antimycotic solution, L-glutamine and trypsin/EDTA were purchased from 
PAA, Vienna, Austria. Fetal bovine serum (FBS), dimethyl sulfoxide (DMSO) and 3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) were obtained from Sigma–
Aldrich Chemie GmbH, Germany. Propidium iodide (PI) and annexin V–FITC (AV) were 
purchased from Abcam, Cambridge, UK. Dihydroethidium (DHE) was obtained from Molecular 
Probes
®
, Invitrogen, CA, USA. JC-1 was purchased from BD Pharmingen™, BD Biosciences, 
San Jose, CA, USA.  
Drugs. All compounds were diluted in ethanol and 20 mM aliquots were stored at 4°C. Drugs 
were thawed and diluted in fresh water to 1 mM before use. CDDP was obtained from Pfizer 
(Perth) Pty Ltd, Bentley, Australia and stored as 1 mM stock in H2O. 
Cell culture. NCI-H460 cell line was purchased from the American Type Culture Collection, 
Rockville, MD. NCI-H460/R cells were selected originally from NCI-H460 cells and cultured in 
a medium containing DOX [34]. HaCaT cell line (normal human keratinocytes obtained from 
CLS - Cell Lines Service, Eppelheim, Germany) was a generous gift from Prof. Jörg Andrä, 
Division of Biophysics, Research Center Borstel, Leibniz-Center for Medicine and Biosciences, 
Borstel, Germany. NCI-H460 and NCI-H460/R cells were maintained in RPMI 1640 medium 
supplemented with 10% FBS, 2mM L-glutamine, and 10,000 U/ml penicillin, 10 mg/ml 
streptomycin, 25 g/ml amphotericin B solution. HaCaT cells were cultured in DMEM 
supplemented with 10% FBS, 4 g/L glucose, L-glutamine (2 mM) and 5000 U/ml penicilin, 5 
mg/mL streptomycin solution. NCI-H460 and NCI-H460/R cells were subcultured at 72 h 
intervals using 0.25% trypsin/EDTA and seeded into a fresh medium at 8,000 and 16,000 
cells/cm
2
, respectively. HaCaT cells were subcultured at 144 h intervals using 0.25% 
trypsin/EDTA and seeded into a fresh medium at 64,000 cells/cm
2
. 
Cytotoxicity by MTT assay. Cell viability was assessed by MTT assay based on the reduction of 
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide into formazan dye by active 
mitochondria of living cells. Briefly, cells were placed in 96-well microplates at following 
densities: 1000 cells/well for NCI-H460, 2000 cells/well for NCI-H460/R and 4000 cells/well for 
HaCaT in 100 μL of adequate medium. After 24 h, cells were treated with compounds and 
incubated for additional 72 h. MTT was added to final concentration of 0.4 mg/mL in each well 
of a 96-well microplate and plates were incubated at 37 °C for 4 h. Media were discarded and 100 
μL DMSO was added to dissolve formazan product, the amount of which was proportional to the 
number of live cells. The absorbance of the dissolved dye was measured at 540 nm using an 
automatic microplate reader (LKB 5060-006 Micro Plate Reader, Vienna, Austria). 
Growth inhibition (I) was determined according to the following equitation: 
I (%) = (1 – (A treated sample/A untreated control)) x 100, where A is absorbance. 
IC30 and IC50 values were defined as concentration of each drug that inhibited cell growth by 30% 
and 50%, respectively. These values were calculated by linear regression analysis using Excel 
software. 
Cell death detection. The percentages of apoptotic, necrotic and viable cells were determined by 
annexin V–FITC (AV) and propidium iodide (PI) labeling. NCI-H460 and NCI-H460/R cells 
were plated and incubated overnight in 6-well plates at density of 50,000 cells/well, while HaCaT 
cells were seeded at density of 100,000 cells/well. Cells were subjected to single treatments with 
25 M TBQ (1) and its derivatives as well as avarone (2) and its derivatives. CDDP was used as 
a control compound in concentration of 5 µM.  After 72 h, the attached and floating cells were 
collected by centrifugation. The cells pellet was re-suspended in 100 μL of binding buffer 
supplemented with 5 μl AV and 5 μl PI according to manufacturer’s instructions. After the 
incubation period (5 min at room temperature), additional 400 μL of binding buffer was added 
and AV/PI staining was analyzed within 1 h by flow-cytometry. The fluorescence intensity 
(green FL1-H and red FL2-H) was measured on FACSCalibur flow-cytometer (Becton 
Dickinson, Oxford, United Kingdom). In each sample, 10,000 cells were recorded (gated to 
exclude cell debris), and the percentages of viable (AV–PI–), early apoptotic (AV+PI–), 
apoptotic and necrotic (AV+PI+), and already dead (AV–PI+) cells were analyzed by CellQuest 
Pro data analysis software. 
Superoxide anion detection. Flow-cytometric analysis of DHE fluorescence intensity was used 
to detect superoxide anion level in cells. NCI-H460 and NCI-H460/R cells were plated and 
incubated overnight in 6-well plates at density of 50,000 cells/well, while HaCaT cells were 
seeded at density of 100,000 cells/well. Cells were treated with 25 μM of TBQ (1) and its 
derivatives as well as avarone (2) and its derivatives. CDDP was used as a control compound in 
concentration of 5 µM. After 72 h, adherent cells were harvested by trypsinization and incubated 
in adequate medium with 1 μM DHE for 30 min at 37 °C in the dark. Cells were subsequently 
washed twice in PBS and DHE fluorescence was analyzed by flow-cytometry (excitation 488 nm, 
and emission 585 nm, FL2-H channel). Mean fluorescence intensity (MFI) was calculated after 
correction for auto-fluorescence. 
 JC-1 assay. JC-1 is a cationic dye whose accumulation in mitochondria is dependent on the 
mitochondrial membrane potential. Under normal conditions, JC-1 accumulates in healthy 
mitochondria as red aggregates detectable in FL2-H channel in flow-cytometer while in 
mitochondria with depolarized ΔΨm the dye remains in the cytoplasm in monomeric form 
detectable in FL1-H channel as green fluorescence. Thus, in mitochondria undergoing a transition 
from polarized to depolarized ΔΨm, JC-1 leaks out of the mitochondria into the cytoplasm 
resulting in an increase in green fluorescence and a decrease in red fluorescence. 
According to the manufacturer’s instructions, cells were incubated with a JC-1 reagent for 15 min 
at 37 °C in CO2 incubator. After two washings in 1 x Assay Buffer, the cells were re-suspended 
in PBS prior flow-cytometric analysis. 
JC-1 stained live cells were also examined under the Zeiss Axiovert fluorescent microscope (Carl 
Zeiss Foundation, Oberkochen, Germany) using an AxioVision4.6 software. 
Statistical analysis. Statistical analysis was performed by GraphPad Prism 6 Software. In MTT 
assay analysis, the differences between groups were tested by Student’s t-test and were 
considered statistically significant if p < 0.05. Flow cytometry results were examined by Two-
way ANOVA and analyzed by Tukey's multiple comparisons test.  
Antimicrobial Activity Determination. Antimicrobial activity was evaluated using a broth 
microdilution method according to NCCLS [35]. Test compounds were dissolved in DMSO to a 
stock concentration of 10 mg/mL and dilluted in the Mueller Hinton broth for bacteria or 
Sabouraund dextrose broth for fungi. Amikacin served as positive control for bacteria, while 
nystatin served as positive control for fungi. Gram-negative bacterial strains used were: 
Escherichia coli (ATCC 25922), Pseudomonas aeruginosa (ATCC 9027), Proteus hauseri 
(ATCC 13315) and Salmonella enterica subsp. enterica serovar Enteritidis  (ATCC 13076). 
Gram-positive bacterial strains used were: Bacillus subtilis (ATCC 6633), Clostridium 
sporogenes (ATCC 19404), Streptosporangium longisporum (ATCC 25212), Micrococcus luteus 
(ATCC 10240), Micrococcus luteus (ATCC 4698), Kocuria rhizophila (ATCC 9341), and 
Staphylococcus aureus (ATCC 6538). Fungal species used were: Candida albicans (ATCC 
10231), Saccharomyces cerevisiae (ATCC 9763) and Aspergillus brasiliensis (ATCC 16404).  
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 Ec1 Ea1 Ec2 Ea2 E
0
1/Fc 
3a -1.200 -1.104 -1.910 -1.785 -1.213 
4a -1.200 -1.124 -1.906 -1.766 -1.223 
3b -1.160 -1.080 -1.896 -1.746 -1.191 
4b -1.170 -1.102 -1.860 -1.672 -1.211 
3c -1.160 -1.081 -1.892 -1.759 -1.192 
4c -1.182 -1.096 -1.921 -1.773 -1.210 
3d -1.183 -1.095 -1.917 -1.806 -1.200 
4d -1.199 -1.116 -1.933 -1.785 -1.219 
3e -1.128 -1.053 -1.800 -1.619 -1.159 
4e -1.141 -1.071 -1.803 -1.593 -1.174 
3f -1.135 -1.069 -1.889 -1.749 -1.174 
4f -1.147 -1.084 -1.873 -1.728 -1.188 
3g -1.138 -1.067 -1.876 -1.747 -1.172 
4g -1.148 -1.078 -1.888 -1.749 -1.182 
3h -1.132 -1.059 -1.852 -1.711 -1.165 
4h -1.144 -1.076 -1.849 -1.684 -1.179 
3i -1.123 -1.052 -1.876 -1.747 -1.156 
4i -1.131 -1.061 -1.869 -1.729 -1.164 
 
Table 2. Cytotoxic activity of avarone, TBQ and their derivatives in non-small cell lung 
carcinoma cell lines (NCI-H460 – sensitive and NCI-H460/R – MDR variant) as well as in 
human normal keratinocytes HaCaT 
Compounds 
NCI-H460 NCI-H460/R HaCaT 
IC30 IC50 IC30 IC50 IC30 IC50 
CDDP
c
 2.2  0.3 5.2  0.4 0.7  0.1 1.7  0.1 0.3  0.1 0.7  0.1 
1
c
 >100 >100 31  2 72  8 41  2 95  4 
2
a,c
 36  2 84  9 10  1 24  4 16  1 37  8 
3a 14  1 25  3 15  1 23  4 8  3 10  4 
4a 34  1 63  2 31  1 58  2 17  1 28  1 
3b
a
 4  2 13  2 5  3 14  5 22  5 30  5 
4b 45  2 64  2 45  1 65  1 50  3 75  4 
3c 4  3 14  3 4  1 13  1 7  2 11  2 
4c
a,b
 5  2 36  1 19  1 72  3 50  2 >100 
3d
a
 5  1 20  3 8  1 21  3 18  2 30  2 
4d
a
 18  3 70  1 21  1 65  3 >100 >100 
3e
a,c
 5  1 14  2 3  2 10  2 12  2 21  1 
4e
a,c
 13  1 19  4 5  1 15  2 12  1 28  2 
3f 
a,c
 7  2 14  1 3  1 6  1 19  1 23  2 
4f
 a 
17  2 35  3 11  1 33  2 >100 >100 
3g
c
 9  2 16  2 3  1 6  2 11  1 16  4 
4g
a,c
 91  1 >100 24  2 >100 86  2 >100 
3h 21  1 38  3 13  1 35  1 13  2 17  7 
4h
a
 >100 >100 >100 >100 >100 >100 
3i
a,c
 14  1 21  4 6  1 11  1 18  3 23  4 
4i
a,c
 75  1 >100 10  1 91 1 76  3 >100 
 
a
 Selectivity towards cancer cells (IC30 or IC50 of cancer cells either sensitive or MDR ≤ 1.5 fold than IC30 or IC50 of 
normal cells. The activity od 4h is shown in Fig. S1) 
b
 Resistance (lower efficacy in NCI-H460/R compared to NCI-H460) (IC30 or IC50 of sensitive cancer cells ≤ 1.5 fold 
than IC30 or IC50 of corresponding MDR cells) 
c
 Selectivity towards MDR cells (higher efficacy in NCI-H460/R compared to NCI-H460) (IC30 or IC50 of sensitive 
cancer cells ≥ 1.5 fold than IC30 or IC50 of corresponding MDR cells) 
 
Table 3. Cell death induction by tert-butyl compounds 3d, 4d, 3f, 4f and their sesquiterpene 




Live Cells Apoptotic Cells Dead Cells 
AV–PI– AV+PI– AV+PI+ AV–PI+ 
NCI-H460     
control 98.3 0.3 0.2 1.2 
CDDP 66.0 1.6 5.2 27.2 
1 95.2 0.5 0.5 3.8 
2 74.0 3.4 16.3 6.3 
3d 54.9 0.2 2.9 42.0 
4d 80.9 0.1 1.7 17.3 
3f 66.1 2.4 9.5 22 
4f 80.8 0.8 5.4 13 
3h 95.7 0.1 0.3 3.9 
4h 95.1 0.0 0.3 4.6 
3i 71.7 0.1 0.2 28 
4i 92 0.3 0.5 7.2 
NCI-H460/R     
control 96.4 1.1 1 1.5 
CDDP 55.3 3.8 13.3 27.6 
1 95.2 0.5 1.2 3.1 
2 65.8 2.6 22.7 8.9 
3d 61.4 0.1 2.1 36.4 
4d 83.9 0.2 1.9 14.0 
3f 45.9 2 11.8 40.3 
4f 81 1.3 3.6 14.1 
3h 92.6 0.0 0.1 7.3 
4h 96.1 0.1 0.7 3.1 
3i 53 1.2 3.5 42.3 
4i 94.9 0.4 0.6 4.1 
HaCaT     
control 96.8 0.2 0.2 2.8 
CDDP 53.5 1.4 9.0 36.1 
1 86.8 1.9 3.8 7.5 
2 78.3 2.5 10.1 9.1 
3d 77.0 0.6 2.6 19.8 
4d 93.8 0.0 0.5 5.7 
3f 74.8 4.1 6.9 14.2 
4f 89.2 0.8 1.7 8.3 
3h 85.3 0.3 0.6 13.8 
4h 93.4 0.1 0.7 5.8 
3i 58.1 0.2 0.4 41.3 
4i 89.5 0.3 1 9.2 















































           
3a 0.051 0.813 1.621 0.202 1.621 1.621 0.202 1.621 1.621 3.238 
4a 0.025 0.409 0.813 0.103 0.831 0.813 0.104 0.813 0.813 1.621 
3b 0.024 0.381 0.758 0.024 0.758 0.758 0.024 0.758 0.381 0.758 
4b 0.096 0.758 1.512 0.048 1.512 1.512 0.188 1.512 0.758 3.019 
3c 0.009 / 1.237 0.009 0.154 1.237 0.009 / 0.62 0.62 
4c 0.038 2.47 1.237 0.038 2.47 1.237 0.019 1.237 0.62 0.62 
3d / / / / / / / / / / 
4d 4.295 4.295 4.295 2.147 4.295 2.147 4.295 2.147 2.147 2.147 
3e 0.009 / 2.323 0.009 4.646 2.323 0.009 / 4.646 2.323 
4e 0.072 4.646 4.646 0.018 2.323 2.323 0.036 2.323 4.646 4.646 
3f 0.009 17.667 4.416 0.034 2.208 4.416 0.009 17.667 4.416 4.416 
4f / 2.208 4.416 4.416 2.208 2.208 / 2.208 4.416 2.208 
3g / / / / / / / / / / 
4g / / / / / / / / / / 
3h / / / / / / / / / / 
4h / / / / / / / / / / 
3i / / / / / / / / / / 
4i / / / / / / / / / / 
Amikacin 0.019 0.003 0.072 0.014 0.003 0.026 0.009 0.012 0.014 0.085 





C. albicans S. cerevisiae A. brasiliensis 
3a 1.621 3.238 0.103 
4a 1.621 1.621 0.051 
3b 1.512 1.512 0.048 
4b 1.512 3.019 0.381 
3c 0.077 0.154 0.620 
4c 0.077 0.154 2.464 
3d 0.067 0.539 2.147 
4d 4.295 4.295 2.147 
3e 2.323 2.323 2.323 
4e / / / 
3f 0.034 0.034 1.106 
4f 2.208 2.208 1.106 
3g / / / 
4g / / / 
3h / / / 
4h / / / 
3i / / / 
4i / / / 




























Figure 1. Cyclic voltammogram of compounds 3d and 3h 
 
 
Figure 2. The impact of quinone derivatives on superoxide anion production. Mean DHE 
fluorescence detected in NCI-H460, NCI-H460/R and HaCaT cells treated with 5 μM of CDDP 
and 25 μM of 1, 2, 3d, 4d, 3h, 4h, 3f, 4f 3i and 4i evaluated by flow-cytometry (A). Statistically 
significant difference compared to corresponding untreated control: p<0.001 (***). Flow-
cytometric profile of cells untreated and treated with 25 μM of 3d and 3f (B) 
 
Figure 3. Selective  loss  of  mitochondrial  transmembrane  potential  (ΔΨm)  in  cancer  cells. 
 
Mitochondria of NCI-H460, NCI-H460/R and HaCaT cells untreated and treated with 5 μM 
CDDP and 25 μM  TBQ (1) and its derivatives 3d and 3f were labeled with JC-1 for 15 min at 37 
°C for flow-cytometric analysis (A) and  live imaging on a fluorescent microscope (B). Scale bar 
= 50 μm. Statistically significant difference compared to corresponding untreated control: p<0.05 
(*), p<0.01 (**), p<0.001 (***)
Figure 1. 
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